Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLOD2 | O00469 | 3/20 | 0.60 |
| ▸ | PLOD3 | O60568 | 2/20 | 0.50 |
| ▸ | PLOD1 | Q02809 | 2/20 | 0.50 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.45 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.45 |
| ▸ | TAS1R2 | Q8TE23 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.43 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.43 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.43 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1349410 | 0.87 | PLOD2 (0.59) | PLOD2PLOD3PLOD1TSHRNPC1 | |
| SCHEMBL1925141 | 0.85 | PLOD2 (0.66) | PLOD2PLOD3PLOD1TAS1R3TAS1R1 | |
| SCHEMBL15741514 | 0.82 | TAS1R3 (0.41) | PLOD2TAS1R3TAS1R1TAS1R2SMN1; SMN2 | |
| SCHEMBL4712029 | 0.81 | NPC1 (0.47) | TAS1R3TAS1R1TAS1R2SMN1; SMN2KCNQ3 | |
| SCHEMBL584065 | 0.81 | PLOD2 (0.70) | PLOD2PLOD3PLOD1TSHRNPC1 | |
| SCHEMBL1924352 | 0.81 | PLOD2 (0.60) | PLOD2PLOD3PLOD1TAS1R3TAS1R1 | |
| SCHEMBL2256181 | 0.80 | TAS1R3 (0.49) | TAS1R3TAS1R1TAS1R2SMN1; SMN2KCNQ3 | |
| SCHEMBL1348683 | 0.79 | PLOD2 (0.54) | PLOD2PLOD3PLOD1TAS1R3TAS1R1 | |
| SCHEMBL6166658 | 0.79 | PLOD2 (0.50) | PLOD2PLOD3PLOD1TAS1R3TAS1R1 | |
| SCHEMBL1927100 | 0.79 | ERCC5 (0.61) | PLOD2PLOD3PLOD1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2531503-A1 | GAMMA SECRETASE MODULATERS | F. Hoffmann-La Roche AG (CH) | 2012-12-12 | — | — | EP | disclosed |
| WO-2011092272-A1 | GAMMA SECRETASE MODULATERS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-04 | — | — | WO | disclosed |
| US-20110190269-A1 | GAMMA SECRETASE MODULATORS | HOFFMANN-LA ROCHE, INC. | 2011-08-04 | — | — | US | disclosed |
| EP-1670801-B1 | PYRAZOLO AND IMIDAZO-PYRIMIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-06-08 | — | — | EP | disclosed |
| US-7514443-B2 | Substituted pyrazolo[1,5-a]pyrimidines as inhibitors of metabotropic glutamate receptors | HOFFMANN-LA ROCHE INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20080051421-A1 | Pyrazolo-pyridine | WICHMANN JUERGEN | 2008-02-28 | — | — | US | disclosed |
| US-7329662-B2 | Pyrazolo-pyridine | HOFFMANN-LA ROCHE INC. (US) | 2008-02-12 | — | — | US | disclosed |
| CN-1890242-A | Pyrazolo and imidazo-pyrimidine derivatives | HOFFMANN LA ROCHE (CH) | 2007-01-03 | — | — | CN | disclosed |
| EP-1670801-A1 | PYRAZOLO AND IMIDAZO-PYRIMIDINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2006-06-21 | — | — | EP | disclosed |
| US-20050130992-A1 | Pyrazolo-pyridine | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-16 | — | — | US | disclosed |
| WO-2005040171-A1 | PYRAZOLO AND IMIDAZO-PYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130992-A1 | Pyrazolo-pyridine | CHRM2, CHRM1, QDPR | PLOD2 3738/4885PLOD3 3474/4885PLOD1 3848/4885 |
| US-20110190269-A1 | GAMMA SECRETASE MODULATORS | BACE1, APH1A, APH1B | PLOD2 2219/4885PLOD3 1004/4885PLOD1 2807/4885 |
| US-20080051421-A1 | Pyrazolo-pyridine | CHRM2, CHRM1, QDPR | PLOD2 3738/4885PLOD3 3474/4885PLOD1 3848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.